News

The transaction is valued at EUR1.7m including cash and stock, plus earn-out consideration of cash and stock with a value of up to EUR1.5m. Kai Lindevall, executive officer

Wyeth and Nycomed’s request for FDA to reset the date of Teva’s final approval to January 2011, based on the fact that Teva has patent defenses remaining at

Reportedly, prior to joining Illumina, Dr Cimler served as president of PandiaDx Consulting, where she provided regulatory and compliance guidance for the development of in vitro diagnostics products

Good Health is voluntarily recalling the product as it is being informed by the FDA that a lab analyses found that the product tested from certain batches of

Medgenics is a commercial-stage biopharmaceutical company, developing tissue-based Biopump platform technology to provide sustained-action protein therapy for the treatment of a range of chronic diseases. Biopumps are made

Lorus claimed that the drug has shown selective and potent antitumor activity in preclinical investigations with a variety of human cancers, including colon cancer and non-small cell lung

Cytosol develops anticoagulants and other products to aid in the processing of blood components. The company has three proprietary products with new drug application approvals: TriCitrasol, noClot-50 and

The current study was initiated to evaluate the safety and efficacy of TJSL Capsules among 440 patients with primary dysmenorrheal. TJSL Capsules is a novel investigational drug to

Nitto Denko and Quark Pharma are expected to develop siRNA drugs using Quark’s RNAi technologies and new structures providing freedom to operate in the siRNA intellectual property space